humulene and Somatoform-Disorders

Cannabis use in the United States is growing at an unprecedented pace. Most states in the United States have legalized medical cannabis use, and many have legalized nonmedical cannabis use. In this setting, health care professionals will increasingly see more patients who have questions about cannabis use, its utility for medical conditions, and the risks of its use. This narrative review provides an overview of the background, pharmacology, therapeutic use, and potential complications of cannabis.

Topics: Adult; Cachexia; Cannabis; Endocannabinoids; Female; Health Personnel; Humans; Legislation, Drug; Male; Medical Marijuana; Nausea; Neurobiology; Opioid-Related Disorders; Seizures; Severity of Illness Index; Somatoform Disorders; Spasm; Stress Disorders, Post-Traumatic; United States

Topics: Cannabis; Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Psychoses, Substance-Induced; Somatoform Disorders

Cannabidiol (CBD)-based treatments for several diseases, including Tourette's syndrome, multiple sclerosis, epilepsy, movement disorders and glaucoma, are proving to be beneficial and the scientific clinical background of the drug is continuously evolving.. To investigate the short-term effect of CBD-enriched hemp oil for relieving symptoms and improving the life quality (QOL) in young girls with adverse drug effects (ADRs) following human papillomavirus (HPV) vaccine.. In this anecdotal, retrospective, "compassionate-use", observational, open-label study, 12 females (age 12-24 years) with severe somatoform and dysautonomic syndrome following HPV vaccination were given sublingual CBD-rich hemp oil drops, 25 mg/kg per day supplemented by 2-5 mg/ml CBD once a week until a maximum dose of 150 mg/ml CBD per day was reached over a 3 month period. Patients' quality of life was evaluated using the medical outcome short-form health survey questionnaire (SF-36).. Two patients dropped out due to iatrogenic adverse events and another two patients stopped the treatment early due to lack of any improvement. SF-36 showed significant benefits in the physical component score (P < 0.02), vitality (P < 0.03) and social role functioning (P < 0.02) after the treatment. The administration of hemp oil also significantly reduced body pain according to the SF-36 assessment. No significant differences from the start of treatment to several months post-treatment were detected in role limitations due to emotional reactions (P = 0.02).. This study demonstrated the safety and tolerability of CBD-rich hemp oil and the primary efficacy endpoint. Randomized controlled trials are warranted to characterize the safety profile and efficacy of this compound.

Topics: Administration, Sublingual; Adolescent; Autonomic Nervous System; Cannabidiol; Cannabinoid Receptor Agonists; Cannabis; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Female; Humans; Italy; Papillomavirus Vaccines; Plant Oils; Primary Dysautonomias; Quality of Life; Retrospective Studies; Somatoform Disorders; Treatment Outcome; Young Adult

Over 4400 adult internet users completed The Center for Epidemiologic Studies Depression scale and measures of marijuana use. We employed an internet survey in an effort to recruit the most depressed and marijuana-involved participants, including those who might prove unwilling to travel to the laboratory or discuss drug use on the phone or in person. We compared those who consumed marijuana daily, once a week or less, or never in their lives. Despite comparable ranges of scores on all depression subscales, those who used once per week or less had less depressed mood, more positive affect, and fewer somatic complaints than non-users. Daily users reported less depressed mood and more positive affect than non-users. The three groups did not differ on interpersonal symptoms. Separate analyses for medical vs. recreational users demonstrated that medical users reported more depressed mood and more somatic complaints than recreational users, suggesting that medical conditions clearly contribute to depression scores and should be considered in studies of marijuana and depression. These data suggest that adults apparently do not increase their risk for depression by using marijuana.

Topics: Adult; Affect; Cannabis; Depression; Female; Humans; Illicit Drugs; Internet; Interpersonal Relations; Male; Marijuana Smoking; Population Surveillance; Sex Factors; Somatoform Disorders

Topics: Adult; Cannabis; Chest Pain; Humans; Male; Phytotherapy; Quality of Life; Somatoform Disorders; Time Factors